Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis.
about
The trend of susceptibilities to amphotericin B and fluconazole of Candida species from 1999 to 2002 in Taiwan.Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agentsCryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomesGain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulenceProbing the Active Site ofCandida glabrataDihydrofolate Reductase with High Resolution Crystal Structures and the Synthesis of New InhibitorsCrystal Structures of Candida albicans Dihydrofolate Reductase Bound to Propargyl-Linked Antifolates Reveal the Flexibility of Active Site Loop Residues Critical for Ligand Potency and SelectivityStructural analysis of the active sites of dihydrofolate reductase from two species of Candida uncovers ligand-induced conformational changes shared among speciesSystematic phenotyping of a large-scale Candida glabrata deletion collection reveals novel antifungal tolerance genesAntifungal Therapy: New Advances in the Understanding and Treatment of MycosisFungal PDR transporters: Phylogeny, topology, motifs and function.Isolation, molecular identification, and antifungal susceptibility profiles of vaginal isolates of Candida species.Fungal Profile of Vulvovaginal Candidiasis in a Tertiary Care HospitalProteomic analysis of cytosolic proteins associated with petite mutations in Candida glabrata.Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance.Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole.Contribution of CgPDR1-regulated genes in enhanced virulence of azole-resistant Candida glabrataMilbemycin A4 oxime as a probe of azole transport in Candida glabrataLocal silencing controls the oxidative stress response and the multidrug resistance in Candida glabrata.Microarray and molecular analyses of the azole resistance mechanism in Candida glabrata oropharyngeal isolates.UPC2A is required for high-level azole antifungal resistance in Candida glabrata.Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.Evaluation of reference genes for real-time quantitative PCR studies in Candida glabrata following azole treatment.Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy.Roles of cellular respiration, CgCDR1, and CgCDR2 in Candida glabrata resistance to histatin 5.Candida glabrata PDR1, a transcriptional regulator of a pleiotropic drug resistance network, mediates azole resistance in clinical isolates and petite mutants.Candidemia in the critically ill: initial therapy and outcome in mechanically ventilated patientsAzole resistance of Candida glabrata in a case of recurrent fungemiaCandida glabrata erg1 mutant with increased sensitivity to azoles and to low oxygen tension.Involvement of PDK1, PKC and TOR signalling pathways in basal fluconazole tolerance in Cryptococcus neoformans.Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.Changes in karyotype and azole susceptibility of sequential bloodstream isolates from patients with Candida glabrata candidemia.The Ssk1p response regulator and Chk1p histidine kinase mutants of Candida albicans are hypersensitive to fluconazole and voriconazole.Emerging fungal diseases.An update on antifungal targets and mechanisms of resistance in Candida albicans.STB5 is a negative regulator of azole resistance in Candida glabrataEvaluation of Polymorphic Locus Sequence Typing for Candida glabrata Epidemiology.In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.Clotrimazole Drug Resistance in Candida glabrata Clinical Isolates Correlates with Increased Expression of the Drug:H(+) Antiporters CgAqr1, CgTpo1_1, CgTpo3, and CgQdr2.Gain-of-function mutations in PDR1, a regulator of antifungal drug resistance in Candida glabrata, control adherence to host cells.Efflux-mediated antifungal drug resistance.
P2860
Q24814052-8D2616F5-A822-42C0-903D-DA7BAD2F031DQ26863344-6ADDE3CC-49F8-4979-BF6B-63F3EF157D4FQ27315103-76262C4F-AA10-45FE-A5DD-17EB210DC4C7Q27318203-68AE355F-495F-425C-B425-FA45BFFB2DAEQ27653450-69F31DB8-2F92-4249-AB8D-0FC391DE5A12Q27670663-BC43F854-98D7-46CC-903F-4601BF68F7F1Q27676116-F606B5D8-71E1-492C-90FB-3C43E5C92C5AQ28539874-107708AB-3A13-4375-894F-09C352BECB52Q28818603-6D3FF0E3-5424-474B-8FA8-EAC1F1E61215Q33624643-1DB94EC3-5F1D-4BE6-8A57-EDF4A26AB001Q33645341-2C77E433-0F31-4240-B02C-F9B8CF94878FQ33666272-9F4E9CC7-44EF-4401-A48C-89DAF4488C4CQ33750421-C506A693-5D3F-4D58-AED4-1B1F2AF732C2Q33805788-2AE05820-EA01-40ED-A08B-B8DF953A7B6DQ33806807-3D519890-4F10-4568-97F1-6D4B4234249DQ33847058-A006F794-D9F6-4051-8CAB-28D03BC6F852Q34021031-F1870443-7B22-4EE8-A69F-4528DBC94F89Q34036604-D3C94168-A816-440D-A16D-CD1D297E82E7Q34045265-8ED986A9-96E1-42D6-AA6E-DADC040C034CQ34058180-F19549FC-7094-4ADD-B03A-A7BF14F635CAQ34228354-7045FEEE-4E79-4DB4-88F0-94F38E1CD57EQ34322237-BDD05E0A-3DDE-4BA8-9C54-2BB341D00EFDQ34430768-8CC58889-18C3-4EC6-BD51-633657BB391CQ34509765-86A502D2-733A-4752-9A20-AAF0D63BA552Q34510712-462252C0-9EF0-4640-A61D-9794E4C1E50DQ35028914-D32B0C1D-BE4C-4365-B4DC-0E57994D0506Q35073016-6AEA691D-F164-4D16-82CA-78554F016742Q35124431-094A9E6D-A7F4-4A05-85D7-220235E7D777Q35854764-4DBDADDA-CC5B-4ECB-9810-37AEFD92E246Q35912243-B59CCF4A-7803-4E35-800B-17255A22A017Q35947465-E72C7382-B825-4337-A9E4-8ED19C71C2ABQ36095050-BF40E3D6-7BAD-4682-98B6-EC26FAACCC74Q36199785-4654EA48-7209-4CE5-A637-53179A19047CQ36235037-BFB385D9-6C75-4F42-A80D-E35980CA2A3CQ36558417-12C0226D-933A-4E6E-B8E5-965F873CDF9BQ36734976-511492E4-3131-4B61-ADDE-790B71BCC58FQ36803960-6CB287C2-D4D5-4A15-8DBE-F5B034A44538Q36809333-FD53E0AD-6C64-4F0B-A6A8-023493A2F69EQ36827007-4143AE15-4666-4FD5-8654-FD2964F1DAF1Q37156645-E0C3CE88-8332-4788-BDE3-399D2115EAE8
P2860
Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis.
@en
Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis.
@nl
type
label
Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis.
@en
Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis.
@nl
prefLabel
Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis.
@en
Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis.
@nl
P2093
P2860
P1476
Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis.
@en
P2093
John E Bennett
Kieren A Marr
Koichi Izumikawa
P2860
P304
P356
10.1128/AAC.48.5.1773-1777.2004
P407
P577
2004-05-01T00:00:00Z